CN113117144A - Bionic dermis importing solution and application thereof - Google Patents
Bionic dermis importing solution and application thereof Download PDFInfo
- Publication number
- CN113117144A CN113117144A CN201911399088.8A CN201911399088A CN113117144A CN 113117144 A CN113117144 A CN 113117144A CN 201911399088 A CN201911399088 A CN 201911399088A CN 113117144 A CN113117144 A CN 113117144A
- Authority
- CN
- China
- Prior art keywords
- biomimetic
- infusion solution
- dermal
- collagen
- dermal infusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/60—Materials for use in artificial skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The application discloses a bionic dermis importing solution and application thereof, and relates to the technical field of medical cosmetology. The components of the bionic dermis introduction solution comprise non-crosslinked sodium hyaluronate, collagen, water-soluble chitosan, nicotinamide, riboflavin, phosphate buffer and water. The bionic dermis introduction solution can improve various skin problems such as skin dryness, wrinkles and aging, and has effects of whitening skin, and stimulating collagen expression and regeneration.
Description
Technical Field
The application relates to the technical field of medical cosmetology, in particular to a bionic dermis importing solution and application thereof.
Background
Aging refers to the progressive reduction of the physiological and psychological adaptive capacity of the body to the environment. Aging can be divided into two categories: physiological aging and pathological aging. Physiological aging refers to a physiological degenerative process that occurs after the maturation period. With the generation of photoaging, photoaging and physiological senescence, matrix skeleton components and filling substances such as collagen, sodium hyaluronate, chondroitin sulfate and the like in dermal tissues gradually lose, so that the elasticity of skin is reduced. The generation of wrinkles discounts the image score, the demand of modern women for self image management is increasing, and related technologies are produced in recent years. With the rapid development of modern medical beauty treatment technology and biological material science, the face rejuvenation is more and more favored by using an injection filling beauty treatment method. Injection filling beauty, that is, injecting biological material or artificial synthetic biological material into dermis or subcutaneous, and achieving a large class of non-surgical beauty treatment methods for reducing skin wrinkles or shaping through different action mechanisms, such as botulinum toxin injection beauty treatment products, hyaluronic acid injection beauty treatment products and the like.
Hyaluronic Acid (HA) is a polysaccharide widely present in human tissues, is an unbranched polymeric glycosaminoglycan composed of repeating units of N-acetylglucosamine and D-glucuronosyl, is present in the intercellular spaces of animal tissues, and is present in high amounts in organs such as the skin, joint cavities, eyes, and the like. The HA is absorbed by oral administration through digestion, and researches show that the bioavailability is about 5 percent, the HA synthesis precursor in vivo can be increased, the HA synthesis amount in skin and other tissues is increased, the water retention property of the skin is improved, the skin is rich in elasticity, and wrinkles are reduced. Has the effects of quickly supplementing skin moisture and increasing skin elasticity.
The water soluble chitosan is widely present in the cells of lower plant fungi and algae, shells of crustaceans, shrimps, crabs and insects, cell walls of higher plants and the like, and has the functions of resisting cancers and improving immunity.
The small molecular collagen is collagen biological high molecular substance with molecular weight below 2000 Dalton, and is collagen in the form of small peptide, and can be directly absorbed by human body without decomposition.
Riboflavins, i.e. vitamin B2The flavoenzymes are components of the prosthetic group of the internal flavoenzymes (the flavoenzymes play a hydrogen transfer role in biological oxidation reduction), and when the flavoenzymes are lacked, the biological oxidation of the organism is influenced, so that the metabolism is hindered. The pathological changes of the riboflavin medicament are mainly shown as inflammation of the mouth, eyes and external genitalia, such as angular cheilitis, glossitis, conjunctivitis, scrotitis and the like, and the riboflavin can be used for preventing and treating the diseases. Vitamin B in vivo2Is very limited and is therefore supplied daily by the diet. Vitamin B2Are the main cause of their loss: (1) can be damaged by light; (2) the riboflavin is small molecule and can be injected into skin to achieve rapid introduction.
Nicotinamide, also known as nicotinamide, is an amide compound of nicotinic acid, and is white crystalline powder; no or almost no odor, bitter taste; it is slightly hygroscopic. It is easily soluble in water or ethanol, and soluble in glycerol. The traditional Chinese medicine composition is mainly used for preventing and treating pellagra, stomatitis, glossitis, sick sinus syndrome, atrioventricular block and the like in clinic. The anti-wrinkle ability of nicotinamide is probably a precursor of NADPH, which activates ATP, provides keratinocyte viability, and increases collagen synthesis. The anti-wrinkle effect of the nicotinamide has good synergistic capability, and the nicotinamide is used together with other anti-wrinkle components, such as VA and the like, so that the anti-wrinkle effect is better. One experimental study in japan showed that the improvement rate of wrinkles was 46.2% and 64.3% after 4 weeks and 8 weeks, respectively, and the skin surface became smooth after applying a cosmetic containing 4% niacinamide around the eyes of 30 healthy japanese women.
Disclosure of Invention
The embodiment of the application provides the bionic dermis introduction solution and the application thereof, can improve various skin problems such as dry skin, wrinkles and aging, and has the effects and efficacies of whitening and stimulating the expression and regeneration of collagen.
In order to achieve the above purpose, the present application mainly provides the following technical solutions:
the embodiment of the application provides a bionic dermis importing solution, which comprises the components of non-crosslinked sodium hyaluronate, collagen, water-soluble chitosan, nicotinamide, riboflavin, phosphate buffer and water.
Preferably, the non-crosslinked sodium hyaluronate has a molecular weight of 4000 daltons to 40 ten thousand daltons.
Preferably, the mass fraction of the non-crosslinked sodium hyaluronate in the bionic dermis introduction solution is 0.1-1%.
Preferably, the mass fraction of the non-crosslinked sodium hyaluronate in the bionic dermis introduction solution is 0.5-1%.
Preferably, the collagen is small molecule collagen with a molecular weight of 1000-.
Preferably, the mass fraction of the collagen in the bionic dermis introduction solution is 0.1% -5.5%.
Preferably, the mass fraction of the collagen in the bionic dermis introduction solution is 0.5% -3%.
Preferably, the mass fraction of the water-soluble chitosan in the bionic dermis introduction solution is 0.1% -1%.
Preferably, the mass fraction of the water-soluble chitosan in the bionic dermis introduction solution is 0.5-1%.
Preferably, the mass fraction of the nicotinamide in the bionic dermis introduction solution is 10% -15%.
Preferably, the mass fraction of the nicotinamide in the bionic dermis introduction solution is 10% -11%.
Preferably, the mass fraction of riboflavin in the bionic dermis introduction solution is 0.1% -1%.
Preferably, the mass fraction of riboflavin in the bionic dermis introduction solution is 0.5% -1%.
Preferably, the pH value of the bionic dermis introduction solution is 6.5-7.1.
The embodiment of the application also provides application of the bionic dermis introduction solution in medical cosmetology of human faces.
Preferably, the bionic dermal introduction solution is injected into the face at a dose of 2-10mL, the injection period is 1-3 months, and the treatment period is one year.
One or more technical solutions provided in the embodiments of the present application have at least the following technical effects or advantages:
the bionic dermis introduction solution provided by the application can be used for providing main skeleton components of the extracellular matrix of the dermis tissue and simultaneously stimulating the regeneration of the tissue of the basal cell layer, so that the dermis tissue and the basal layer high-expression active collagen are filled in tissue gaps and the extracellular matrix, and the effects of filling, lubricating and brightening are achieved, so that various skin problems such as skin dryness, wrinkles and aging can be improved, and the effects and effects of whitening and stimulating the collagen to express the regeneration are achieved.
Detailed Description
The embodiment of the application provides the bionic dermis introduction solution and the application thereof, can improve various skin problems such as dry skin, wrinkles and aging, and has the effects and efficacies of whitening and stimulating the expression and regeneration of collagen.
In order to solve the above problems, the technical solution in the embodiment of the present application has the following general idea:
the embodiment of the application provides a bionic dermis importing solution, which comprises the components of non-crosslinked sodium hyaluronate, collagen, water-soluble chitosan, nicotinamide, riboflavin, phosphate buffer and water.
The molecular weight of the non-crosslinked sodium hyaluronate in the bionic dermal implant solution is preferably 4000 daltons to 40 ten thousand daltons in the embodiments of the present application. The mass fraction of the non-crosslinked sodium hyaluronate is preferably 0.1 to 1%. More preferably, the mass fraction of the non-crosslinked sodium hyaluronate is 0.5% to 1%.
In the embodiment of the application, the collagen is preferably micromolecular collagen, the molecular weight of the micromolecular collagen is 1000-4000 daltons, and the mass fraction of the collagen in the bionic dermis importing solution is preferably 0.1-5.5%. More preferably, the mass fraction of collagen is 0.5% to 3%.
In the embodiment of the application, the mass fraction of the water-soluble chitosan in the bionic dermis importing solution is preferably 0.1-1%. More preferably, the mass fraction of the water-soluble chitosan is 0.5 to 1%.
In the embodiment of the application, the mass fraction of the nicotinamide in the bionic dermis importing solution is preferably 10-15%. More preferably, the mass fraction of nicotinamide is 10% to 11%.
In the embodiment of the application, the mass fraction of the riboflavin in the bionic dermis introduction solution is preferably 0.1-1%. More preferably, the mass fraction of riboflavin is 0.5% to 1%.
The pH value of the bionic dermis introduction solution is preferably 6.5-7.1 in the embodiment of the application.
The introduction of the non-crosslinked sodium hyaluronate, the small molecular collagen and the chitosan in the bionic dermis introduction solution of the embodiment of the application plays roles and efficacies of filling, moisturizing, water locking, partial anti-inflammation, skin immunity enhancement and collagen expression regeneration stimulation; the introduction of nicotinamide and riboflavin serves to strengthen the dermal tissue, stabilize the sebaceous glands and smooth and brighten the skin condition. The bionic dermis introduction solution provides main skeleton components of a dermal tissue extracellular matrix, and simultaneously stimulates the regeneration of a basal cell layer tissue, so that the dermal tissue and the basal layer high-expression active collagen are filled in tissue gaps and the extracellular matrix, and the effects of filling, lubricating and brightening are achieved, so that various skin problems such as skin dryness, wrinkles and aging can be improved, and the effects and efficacies of whitening and stimulating the collagen to express the regeneration are achieved.
The amounts of the non-crosslinked sodium hyaluronate, collagen, water-soluble chitosan, nicotinamide and riboflavin in the biomimetic dermal implant solution according to the embodiments of the present application are "safe and effective amounts" within the above-mentioned ranges sufficient to significantly improve skin problems without causing serious side effects, and the safe and effective amounts of these components are selected within the above-mentioned ranges according to the age, condition, course of treatment, etc. of the subject.
The bionic dermal introduction solution of the embodiment of the application has a once-through dose of 2mL to 10mL for facial injection, an injection period of 1 month to 3 months, and a treatment period of one year, and the specific injection dose and period can be selected from the above ranges according to the specific conditions of age, disease condition, treatment course and the like of a treated subject.
In order to better understand the technical solutions, the technical solutions will be described in detail with reference to the description and the specific embodiments, but the technical solutions are not limited to the present application.
Example 1
A bionic dermis introduction solution comprises the following components in percentage by mass: 0.5 percent of non-crosslinked sodium hyaluronate, 0.5 percent of small molecule collagen, 0.5 percent of water-soluble chitosan, 10 percent of nicotinamide and 0.5 percent of riboflavin, wherein the molecular weight of the non-crosslinked sodium hyaluronate is 4000 daltons-40 ten thousand daltons, and the molecular weight of the small molecule collagen is 1000-. The preparation method of the bionic dermis introduction solution comprises the following steps: weighing the raw material dosage according to the prescription amount of the non-crosslinked sodium hyaluronate, the micromolecular collagen, the water-soluble chitosan, the nicotinamide and the riboflavin, adding the raw material dosage into the corresponding amount of sterilized water for fully dissolving and mixing, adjusting the pH value of the solution to 6.5 by using the sterilized phosphate buffer solution, and finally carrying out damp-heat sterilization to obtain the sterile bionic dermis introduction solution.
Example 2
A bionic dermis introduction solution comprises the following components in percentage by mass: 0.5 percent of non-crosslinked sodium hyaluronate, 1 percent of small molecule collagen, 0.5 percent of water-soluble chitosan, 10 percent of nicotinamide and 1 percent of riboflavin, wherein the molecular weight of the non-crosslinked sodium hyaluronate is 4000 daltons-40 ten thousand daltons, and the molecular weight of the small molecule collagen is 1000-. The preparation method of the bionic dermis introduction solution comprises the following steps: weighing the raw material dosage according to the prescription amount of the non-crosslinked sodium hyaluronate, the micromolecular collagen, the water-soluble chitosan, the nicotinamide and the riboflavin, adding the raw material dosage into the corresponding amount of sterilized water for fully dissolving and mixing, adjusting the pH of the solution to 6.8 by using the sterilized phosphate buffer solution, and finally carrying out damp-heat sterilization to obtain the sterile bionic dermis introduction solution.
Example 3
A bionic dermis introduction solution comprises the following components in percentage by mass: 1% of non-crosslinked sodium hyaluronate, 0.5% of small molecule collagen, 1% of water-soluble chitosan, 11% of nicotinamide and 0.5% of riboflavin, wherein the molecular weight of the non-crosslinked sodium hyaluronate is 4000 daltons-40 ten thousand daltons, and the molecular weight of the small molecule collagen is 1000-. The preparation method of the bionic dermis introduction solution comprises the following steps: weighing the raw material dosage according to the prescription amount of the non-crosslinked sodium hyaluronate, the micromolecular collagen, the water-soluble chitosan, the nicotinamide and the riboflavin, adding the raw material dosage into the corresponding amount of sterilized water for fully dissolving and mixing, adjusting the pH of the solution to 6.8 by using the sterilized phosphate buffer solution, and finally carrying out damp-heat sterilization to obtain the sterile bionic dermis introduction solution.
Comparative example 1
A dermal delivery solution comprising the following components in parts by mass: 0.5% of non-crosslinked sodium hyaluronate, wherein the molecular weight of the non-crosslinked sodium hyaluronate is from 4000 daltons to 40 kilodaltons. The preparation method of the dermis introduction solution comprises the following steps: weighing the raw material amount according to the prescription amount of the non-crosslinked sodium hyaluronate, adding the raw material amount into the corresponding amount of sterilized water for full dissolution, adjusting the pH of the solution to 6.8 by using the sterilized phosphate buffer solution, and finally performing moist heat sterilization to obtain the sterile dermis introduction solution.
Comparative example 2
A dermal delivery solution comprising the following components in parts by mass: 1% water soluble chitosan. The preparation method of the dermis introduction solution comprises the following steps: weighing the raw material amount according to the prescription amount of the water-soluble chitosan, adding the raw material amount into the corresponding amount of sterilized water for full dissolution, adjusting the pH of the solution to 6.8 by using the sterilized phosphate buffer solution, and finally carrying out damp-heat sterilization to obtain the sterile dermis introduction solution.
Comparative example 3
A dermal delivery solution comprising the following components in parts by mass: 1% of small molecular collagen, wherein the molecular weight of the small molecular collagen is 1000-4000 daltons. The preparation method of the dermis introduction solution comprises the following steps: weighing the raw material amount according to the prescription amount of the micromolecular collagen, adding the raw material amount into the corresponding amount of sterilized water for full dissolution, adjusting the pH of the solution to 6.8 by using the sterilized phosphate buffer solution, and finally carrying out damp-heat sterilization to obtain the sterile dermis introduction solution.
The biomimetic dermal introduction solution of the above example and the dermal introduction solution of the comparative example were subjected to the following performance tests, respectively.
1. Skin moisturization and hydration test
The dermal introduction solutions of examples 1 to 3 and comparative examples 1 to 3 were each subjected to facial injection into 6 subjects, and changes in skin moisture content before and after injection, 1 hour after injection, and 6 hours after injection were measured with a skin moisture measuring instrument, respectively, and the results are shown in table 1.
The results show that the subjects of examples 1-3 and comparative examples 1-3 have high facial hydration levels, with skin hydration levels of example 3 > example 2 > example 1 > comparative example 3 > comparative example 2 after 1 hour and 6 hours of injection. Among them, example 3 was strong in moisturizing ability after 6 hours of injection. It is shown that the biomimetic dermal implant solutions of examples 1-3 of the present application have a good effect of increasing the moisture content of the skin, while the dermal implant solutions of comparative examples 1-3 have only a slight improvement in the water and moisture retention of the skin.
Table 1 skin moisture test results
2. Crease resistance filling Performance test
The dermal introduction solutions of examples 1 to 3 and comparative examples 1 to 3 were each subjected to facial injection to 6 subjects, and the initial wrinkle scores of the selected 6 subjects were consistent, and the anti-wrinkle effects were summarized by VAS scoring methods before injection, 1 month after injection, and 2 months after injection, and the results are shown in table 2. Wherein the total VAS is 10 points, the range value is 0-10, 10 points are no wrinkles, and 0 points are more and deeper wrinkles.
The results showed that the anti-wrinkle effect was example 3 > example 2 > example 1 > comparative example 3 > comparative example 2 after 1 month and 2 months after injection, and that the wrinkle improvement before and after injection of the biomimetic dermal introduction solutions of examples 1 to 3 was very significant, while the wrinkle improvement before and after injection of the dermal introduction solutions of comparative examples 1 to 3 was only slightly improved or hardly improved. It is demonstrated that the biomimetic dermal implant solutions of examples 1-3 have good anti-wrinkle effects.
TABLE 2 skin anti-wrinkle Performance results
3. Skin elasticity test
The dermal introduction solutions of examples 1 to 3 and comparative examples 1 to 3 were each subjected to facial injection to 6 subjects, and the initial skin elasticity scores of the selected 6 subjects were identical, and the skin elasticity scores were summarized by the VAS scoring method before injection, 1 month after injection, and 2 months after injection, and the results are shown in table 3. Wherein the total VAS is 10 points, the range value is 0-10, the skin elasticity is very good when the VAS is 10 points, and the skin elasticity is not good when the VAS is 0 point.
The results showed that the skin elasticity scores were example 3 > example 2 > example 1 > comparative example 3 > comparative example 2 after 1 month after injection, the skin elasticity improvement before and after injection of the biomimetic dermal introduction solutions of examples 1-3 was very significant, and the skin elasticity improvement before and after injection of the dermal introduction solutions of comparative examples 1-3 was only slight or almost no improvement. It is demonstrated that the biomimetic dermal delivery solutions of examples 1-3 have good skin elasticity improving properties.
Table 3 skin elasticity test results
4. Skin lightening and whitening test
The dermal introduction solutions of examples 1 to 3 and comparative examples 1 to 3 were each subjected to facial injection to 6 subjects, and the initial skin lightening and whitening scores of the selected 6 subjects were consistent, and the whitening improvement was examined by VAS scoring method before injection, 1 month after injection, and 2 months after injection, and the results are shown in table 4. Wherein the VAS is 10 minutes in total, the range value is 0-10, 10 is very white skin, and 0 is very black skin.
The results showed that the whitening effect was 1 month after injection, 2 months after injection, example 3 > example 2 > example 1 > comparative example 3 > comparative example 2, the improvement of skin lightening and whitening before and after injection of the biomimetic dermal introduction solutions of examples 1-3 was very significant, and the improvement of skin lightening and whitening before and after injection of the dermal introduction solutions of comparative examples 1-3 was not improved. It is demonstrated that the biomimetic dermal delivery solutions of examples 1-3 have good skin lightening and whitening effects.
Table 4 skin lightening and whitening results
5. Collagen expression assay
The dermal introduction solutions of examples 1 to 3 and comparative examples 1 to 3 were subcutaneously injected into nude mice, and changes in the expression level of type I collagen were examined before and after injection by immunohistochemistry, and the results are shown in Table 5. The results show that collagen I content of examples 1-3 was significantly changed before and after injection, while collagen I of comparative examples 1-3 was not significantly changed. The bionic dermis introduction solution of the embodiment of the application can stimulate the regeneration of the tissue of the basal cell layer, so that the dermis tissue and the basal layer highly express the active collagen.
TABLE 5 type I collagen expression results
Finally, the above embodiments are only used for illustrating the technical solutions of the present application and not for limiting, although the present application is described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions can be made on the technical solutions of the present application without departing from the spirit and scope of the technical solutions of the present application, and all the technical solutions of the present application should be covered by the claims of the present application.
Claims (16)
1. A bionic dermis introduction solution is characterized by comprising non-crosslinked sodium hyaluronate, collagen, water-soluble chitosan, nicotinamide, riboflavin, a phosphate buffer and water.
2. The biomimetic dermal infusion solution of claim 1, wherein the non-crosslinked sodium hyaluronate has a molecular weight of 4000 daltons to 40 ten thousand daltons.
3. The biomimetic dermal infusion solution according to claim 1, wherein the mass fraction of the non-crosslinked sodium hyaluronate in the biomimetic dermal infusion solution is 0.1-1%.
4. The biomimetic dermal infusion solution according to claim 3, wherein the mass fraction of the non-crosslinked sodium hyaluronate in the biomimetic dermal infusion solution is 0.5-1%.
5. The biomimetic dermal infusion solution of claim 1, wherein the collagen is small molecule collagen with a molecular weight of 1000-.
6. The biomimetic dermal infusion solution according to claim 1, wherein the mass fraction of collagen in the biomimetic dermal infusion solution is 0.1-5.5%.
7. The biomimetic dermal infusion solution according to claim 6, wherein the mass fraction of collagen in the biomimetic dermal infusion solution is 0.5-3%.
8. The biomimetic dermal infusion solution according to claim 1, wherein the mass fraction of the water-soluble chitosan in the biomimetic dermal infusion solution is 0.1-1%.
9. The biomimetic dermal infusion solution according to claim 8, wherein the mass fraction of the water-soluble chitosan in the biomimetic dermal infusion solution is 0.5-1%.
10. The biomimetic dermal infusion solution according to claim 1, wherein the mass fraction of niacinamide in the biomimetic dermal infusion solution is 10% to 15%.
11. The biomimetic dermal infusion solution according to claim 10, wherein the mass fraction of niacinamide in the biomimetic dermal infusion solution is 10% to 11%.
12. The biomimetic dermal infusion solution according to claim 1, wherein the mass fraction of riboflavin in the biomimetic dermal infusion solution is between 0.1% and 1%.
13. The biomimetic dermal infusion solution according to claim 12, wherein the mass fraction of riboflavin in the biomimetic dermal infusion solution is between 0.5% and 1%.
14. The biomimetic dermal introduction solution according to claim 1, wherein the pH value of the biomimetic dermal introduction solution is 6.5-7.1.
15. Use of a biomimetic dermal infusion solution according to any of claims 1-14 for medical cosmetic treatment of a human face.
16. The use of the biomimetic dermal infusion solution of claim 15 for medical beauty treatment of human face, wherein the biomimetic dermal infusion solution is administered by facial injection in an amount of 2-10mL once, with an injection period of 1-3 months and a treatment period of one year.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911399088.8A CN113117144A (en) | 2019-12-30 | 2019-12-30 | Bionic dermis importing solution and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911399088.8A CN113117144A (en) | 2019-12-30 | 2019-12-30 | Bionic dermis importing solution and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113117144A true CN113117144A (en) | 2021-07-16 |
Family
ID=76768978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911399088.8A Pending CN113117144A (en) | 2019-12-30 | 2019-12-30 | Bionic dermis importing solution and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113117144A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113813198A (en) * | 2021-09-24 | 2021-12-21 | 西安莲韵医疗美容医院有限公司 | Nutrient solution for improving facial wrinkles and firming skin and preparation method thereof |
Citations (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050249760A1 (en) * | 2004-05-04 | 2005-11-10 | Sun Shin-Ching | Human body affinitive lubricating protective and repair gel |
| CN101693108A (en) * | 2009-10-09 | 2010-04-14 | 南京大渊美容保健有限公司 | Oral nutrition composition for beautifying skin |
| CN102229705A (en) * | 2011-06-02 | 2011-11-02 | 陕西巨子生物技术有限公司 | Collagen temperature-sensitive hydrogel and preparation method thereof |
| CN102321248A (en) * | 2011-06-10 | 2012-01-18 | 冯淑芹 | Injectable temperature sensitive gel used for filling and repairing damaged tissues |
| WO2012085835A2 (en) * | 2010-12-20 | 2012-06-28 | L'oreal | Sterile liquid composition for filling wrinkles |
| CN104207947A (en) * | 2014-08-18 | 2014-12-17 | 贵州捷欣合金技术开发有限公司 | Preparation method for film-forming liquid |
| WO2015020982A2 (en) * | 2013-08-04 | 2015-02-12 | Aquavit Pharmaceuticals, Inc. | Direct application system and method for the delivery of bioactive compositions and formulations |
| US20150238527A1 (en) * | 2012-08-10 | 2015-08-27 | Aquavit Pharmaceuticals, Inc. | Vitamin supplement compositions for injection |
| US20160000683A1 (en) * | 2013-02-28 | 2016-01-07 | Amorepacific Corporation | Composition for maintaining effect of filler |
| CN105233270A (en) * | 2015-11-12 | 2016-01-13 | 上海昊海生物科技股份有限公司 | Medicine composition for water-optical treatment and application of medicine composition |
| CN106215244A (en) * | 2016-08-03 | 2016-12-14 | 爱美客技术发展股份有限公司 | The compound recipe solution of hyaluronate sodium and the application of correction wrinkle of skin thereof |
| CN108186487A (en) * | 2018-02-28 | 2018-06-22 | 北京花鲜素国际贸易有限公司 | Water light stoste and preparation method thereof |
| CN108261341A (en) * | 2018-02-12 | 2018-07-10 | 苏州纳晶医药技术有限公司 | Two-component is used to correct the long-acting water laser accunputure agent of whitening of wrinkle of skin |
| CN108653818A (en) * | 2018-05-24 | 2018-10-16 | 上海其胜生物制剂有限公司 | A kind of reversible collagen stimulation filler and preparation method thereof |
| CN108785843A (en) * | 2017-04-26 | 2018-11-13 | 山东卫康医学美容科技有限公司 | A kind of beauty method |
| CN109044948A (en) * | 2018-09-30 | 2018-12-21 | 白晋 | A kind of autologous collagen albumen water laser accunputure and preparation method thereof |
| EP3427790A1 (en) * | 2017-07-14 | 2019-01-16 | Pixium Vision SA | Photosensitive array |
| CN109528642A (en) * | 2018-12-27 | 2019-03-29 | 上海欧邦医疗管理有限公司 | A kind of autogenous repairing nutrient injection and its application method |
| CN110279888A (en) * | 2019-07-18 | 2019-09-27 | 王月玲 | A kind of injection Ago-Gel agent and preparation method thereof |
-
2019
- 2019-12-30 CN CN201911399088.8A patent/CN113117144A/en active Pending
Patent Citations (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050249760A1 (en) * | 2004-05-04 | 2005-11-10 | Sun Shin-Ching | Human body affinitive lubricating protective and repair gel |
| CN101693108A (en) * | 2009-10-09 | 2010-04-14 | 南京大渊美容保健有限公司 | Oral nutrition composition for beautifying skin |
| WO2012085835A2 (en) * | 2010-12-20 | 2012-06-28 | L'oreal | Sterile liquid composition for filling wrinkles |
| CN102229705A (en) * | 2011-06-02 | 2011-11-02 | 陕西巨子生物技术有限公司 | Collagen temperature-sensitive hydrogel and preparation method thereof |
| CN102321248A (en) * | 2011-06-10 | 2012-01-18 | 冯淑芹 | Injectable temperature sensitive gel used for filling and repairing damaged tissues |
| US20150238527A1 (en) * | 2012-08-10 | 2015-08-27 | Aquavit Pharmaceuticals, Inc. | Vitamin supplement compositions for injection |
| US20160000683A1 (en) * | 2013-02-28 | 2016-01-07 | Amorepacific Corporation | Composition for maintaining effect of filler |
| WO2015020982A2 (en) * | 2013-08-04 | 2015-02-12 | Aquavit Pharmaceuticals, Inc. | Direct application system and method for the delivery of bioactive compositions and formulations |
| CN104207947A (en) * | 2014-08-18 | 2014-12-17 | 贵州捷欣合金技术开发有限公司 | Preparation method for film-forming liquid |
| CN105233270A (en) * | 2015-11-12 | 2016-01-13 | 上海昊海生物科技股份有限公司 | Medicine composition for water-optical treatment and application of medicine composition |
| CN106215244A (en) * | 2016-08-03 | 2016-12-14 | 爱美客技术发展股份有限公司 | The compound recipe solution of hyaluronate sodium and the application of correction wrinkle of skin thereof |
| CN108785843A (en) * | 2017-04-26 | 2018-11-13 | 山东卫康医学美容科技有限公司 | A kind of beauty method |
| EP3427790A1 (en) * | 2017-07-14 | 2019-01-16 | Pixium Vision SA | Photosensitive array |
| CN108261341A (en) * | 2018-02-12 | 2018-07-10 | 苏州纳晶医药技术有限公司 | Two-component is used to correct the long-acting water laser accunputure agent of whitening of wrinkle of skin |
| CN108186487A (en) * | 2018-02-28 | 2018-06-22 | 北京花鲜素国际贸易有限公司 | Water light stoste and preparation method thereof |
| CN108653818A (en) * | 2018-05-24 | 2018-10-16 | 上海其胜生物制剂有限公司 | A kind of reversible collagen stimulation filler and preparation method thereof |
| CN109044948A (en) * | 2018-09-30 | 2018-12-21 | 白晋 | A kind of autologous collagen albumen water laser accunputure and preparation method thereof |
| CN109528642A (en) * | 2018-12-27 | 2019-03-29 | 上海欧邦医疗管理有限公司 | A kind of autogenous repairing nutrient injection and its application method |
| CN110279888A (en) * | 2019-07-18 | 2019-09-27 | 王月玲 | A kind of injection Ago-Gel agent and preparation method thereof |
Non-Patent Citations (8)
| Title |
|---|
| （意）加布里埃拉•法布罗奇尼等主编: "《微创唇周与眼周年轻化技术》", 28 February 2019, 上海：上海科学技术出版社 * |
| 卢丙仑: "水光针的适用人群及副作用", 《微医：HTTPS://BBS.GUAHAO.COM/TOPIC/UETVN91434657710669826》 * |
| 吴溯帆: "注射美容及其安全性", 《中国美容整形外科杂志》 * |
| 申汶锡著: "《埋线提升与抗衰老操作手册》", 31 August 2015, 沈阳：辽宁科学技术出版社 * |
| 秦益民: "《高新纺织材料研究与应用丛书 海洋源生物活性纤维》", 31 August 2019, 北京：中国纺织出版社 * |
| 蔡美琴著: "《"养"出美丽来》", 30 November 2009, 上海：上海交通大学出版社 * |
| 邬佳敏等: "非交联玻尿酸复合氨甲环酸局部注射治疗外伤后皮肤色素沉着临床疗效观察", 《实用医院临床杂志》 * |
| 金海波等主编: "《精修线雕 埋线抗衰老综合临床实用指南》", 31 March 2018, 沈阳：辽宁科学技术出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113813198A (en) * | 2021-09-24 | 2021-12-21 | 西安莲韵医疗美容医院有限公司 | Nutrient solution for improving facial wrinkles and firming skin and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20060040895A1 (en) | Aesthetic use of hyaluronan | |
| CN103415307A (en) | Hyaluronic acid composition | |
| BR112015031026B1 (en) | method for crosslinking hyaluronic acid or one of its salts or other biocompatible polymers; method for preparing an injectable hydrogel; hydrogel; kit and use | |
| CN104394934A (en) | Composition, in an aqueous medium, including at least one hyaluronic acid and at least one sucrose octasulphate water-soluble salt | |
| CN107468563A (en) | A kind of anti-dandruff silk quality lubrication is without silicone oil shampoo | |
| CH705713B1 (en) | Dermocosmetic composition with filling action, useful e.g. for smoothing wrinkles or furrows in epidermis by topical application, comprises mixture containing hyaluronic acids, which includes e.g. hyaluronic acid crosspolymer, and carrier | |
| CN106420482A (en) | Skin energy activating sparkling essence | |
| CN104814901B (en) | One kind prevention striae of pregnancy gel and preparation method thereof | |
| CN113133534A (en) | Tranquilizing and relieving sustained-release oral liquid and preparation method thereof | |
| CN113017093A (en) | Composition with functions of maintaining beauty, keeping young and helping sleep and preparation method thereof | |
| US20050084518A1 (en) | Health food containing hyaluronic acid and dermatan sulfate | |
| CN1771986A (en) | Orally taken joint function protectant | |
| CN113117144A (en) | Bionic dermis importing solution and application thereof | |
| CN113826908A (en) | Functional product with physique strengthening and anti-aging effects and preparation method thereof | |
| CN117357634A (en) | Protein injection and preparation method thereof | |
| RU2737380C2 (en) | Combined agent for intraarticular administration | |
| CN105982911A (en) | Preparation method of high-viscoelasticity injection composed of glucosamine and sodium hyaluronate | |
| KR101917026B1 (en) | Cosmetic composition for skin wrinkle improvement and prevention | |
| CN107802516A (en) | A kind of long-acting preserving moisture and protecting skin Essence | |
| CN113473963A (en) | Cosmetic/dermatological composition | |
| CN114533654A (en) | Low-molecular chondroitin sulfate composite hydrogel and preparation method and application thereof | |
| CN112754981A (en) | Collagen regeneration promoting preparation and preparation method and application thereof | |
| CN101297705A (en) | Compound Tibet sheep placenta capsule for removing wrinkle and resisting aging | |
| RU2726001C1 (en) | Aquaplant biologically active composition | |
| CN107595666A (en) | A kind of long-acting moisture-keeping essence |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |